However, clinical trials using combinations of anti-PD-1/PD-L1 mAbs and IMiDs in MM were put on hold by the FDA because of severe adverse events; while combinations of HDACi are only available for patients with advanced melanoma (NCT02935790 and NCT02032810). Here, PDCD1 is linked to melanoma.